Boehringer Ingelheim kicks off €350M R&D center in Germany
In line with its expectations of snagging about 20 new drug approvals over the next seven years, today Boehringer Ingelheim inaugurated a new Germany-based research center, into which the company invested €350 million (more than $386.5 million).
The Biologicals Development Center, situated on Boehringer’s campus in Biberach, will strengthen its biopharmaceuticals development, which accounts for about 50% of the company’s R&D pipeline. The center is the largest single investment in Germany from the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.